ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.012,09
0,55%
S&P 500
5.996,66
1,00%
Dow Jones
43.487,83
0,78%
Euro vs US Dollar
1,03839
1,04%
Bitcoin
107.679,01
4,40%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Panacea Acquisition Corp (NUVB)

  7. Panacea Acquisition Corp (NUVB) News

NUVB

Panacea Acquisition (NUVB)

Panacea Acquisition Corp
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:NUVB
DatumZeitQuelleÜberschriftSymbolFirma
06/01/202522h05Business WireNuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
06/01/202514h00Business WireNuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung CancerNYSE:NUVBPanacea Acquisition Corp
23/12/202414h00Business WireU.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung CancerNYSE:NUVBPanacea Acquisition Corp
20/12/202413h10PR Newswire (US)Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products AdministrationNYSE:NUVBPanacea Acquisition Corp
26/11/202414h00Business WireNuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNYSE:NUVBPanacea Acquisition Corp
13/11/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
12/11/202422h05Business WireNuvation Bio to Present at the Jefferies London Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
06/11/202422h43Edgar (US Regulatory)Form 8-K - Current reportNYSE:NUVBPanacea Acquisition Corp
06/11/202422h41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NUVBPanacea Acquisition Corp
06/11/202422h05Business WireNuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
10/10/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
09/10/202422h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
09/10/202422h09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
07/10/202422h05Business WireNuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial OfficerNYSE:NUVBPanacea Acquisition Corp
14/09/202409h05Business WirePositive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024NYSE:NUVBPanacea Acquisition Corp
09/09/202414h00Business WireNuvation Bio to Present at the Cantor Global Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
05/09/202422h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
05/09/202422h35Edgar (US Regulatory)Form 8-K - Current reportNYSE:NUVBPanacea Acquisition Corp
16/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:NUVBPanacea Acquisition Corp
15/08/202422h46Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NYSE:NUVBPanacea Acquisition Corp
13/08/202422h02Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNYSE:NUVBPanacea Acquisition Corp
05/08/202422h58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NYSE:NUVBPanacea Acquisition Corp
05/08/202414h44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NUVBPanacea Acquisition Corp
05/08/202414h37Edgar (US Regulatory)Form 8-K - Current reportNYSE:NUVBPanacea Acquisition Corp
05/08/202414h00Business WireNuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
30/07/202422h13Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNYSE:NUVBPanacea Acquisition Corp
30/07/202422h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:NUVBPanacea Acquisition Corp
23/07/202422h05Business WireNuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, TaletrectinibNYSE:NUVBPanacea Acquisition Corp
16/07/202415h03Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNYSE:NUVBPanacea Acquisition Corp
01/06/202414h10Business WireNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual MeetingNYSE:NUVBPanacea Acquisition Corp
 Showing the most relevant articles for your search:NYSE:NUVB

Kürzlich von Ihnen besucht

COIN
AVAXUSD
Avalanche
CCOM
US100
US Tech 100
TG
BAYN
Bayer
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
DBI
TDXP
Tec DAX
TG
DTE
Deutsche Telekom
NYSE
MCD
McDonalds
NYSE
MRK
Merck
PM
XAUUSD
Gold vs US Dollar
DBI
MDAX
MDAX
AMEX
SPY
SPDR S&P 500
FX
EURJPY
Euro vs Yen
COIN
BTCUSD
Bitcoin
TG
ALV
Allianz
COIN
XRPUSD
Ripple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten